載入...
A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma
Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. Administration of the intravenous (IV) formulation is lengthy and places a significant burden on health care resources and patient quality of life. A subcutaneous (sc) formulation...
Na minha lista:
| 發表在: | Curr Oncol |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Multimed Inc.
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5330627/ https://ncbi.nlm.nih.gov/pubmed/28270723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.24.3470 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|